Published in final edited form as:

Ann N Y Acad Sci. 2010 October ; 1207(Suppl 1): E94–102. doi:10.1111/j.1749-6632.2010.05752.x.

Lymphatic system acts as a vital link between metabolic syndrome and inflammation

Sanjukta Chakraborty¹, Scott Zawieja¹, Wei Wang, David C. Zawieja¹, and Mariappan Muthuchamy^{1,*}

¹ Department of Systems Biology and Translational Medicine, Cardiovascular Research Institute, Division of Lymphatic Biology, Texas A&M Health Science Center College of Medicine, College Station, TX

Abstract

Metabolic syndrome is defined by a cluster of different metabolic risk factors that include overall and central obesity, elevated fasting glucose levels, dyslipidemia, hypertension, and intimal atherogenesis. Metabolic syndrome leads to increased risk for the development of type 2 diabetes and cardiovascular disease (e.g., heart disease and stroke). The exacerbated progression of metabolic syndrome to cardiovascular disease has led to intense study of the physiological ramifications of metabolic syndrome on the blood vasculature. These studies have particularly focused on the signaling and architectural alterations that manifest in hypertension and atherosclerosis. However, despite the overlap of metabolic syndrome pathology with lymphatic function, tangent effects on the lymphatic system have not been extensively documented. In this review, we discuss the current status of metabolic syndrome and provide evidence and remaining challenges in the connection between the lymphatic system, lipid transport, obesity, insulin resistance, and general inflammation.

Keywords

metabolic syndrome; lymphatic pump; lymphatics and lipid transport; inflammation

Metabolic syndrome: The disease and its present status

Metabolic syndrome (MS) is defined by a cluster of different metabolic risk factors that include atherogenic dyslipidemia, abdominal obesity, elevated blood pressure and elevated plasma glucose associated with insulin resistance, prothrombotic state, and a pro-inflammatory state. ¹ These risk factors appear to directly promote atherosclerotic cardiovascular disease (ASCVD) and patients are also at an increased risk for type 2 diabetes mellitus. ² MS has become increasingly common in the U.S. and in developing countries including China and India. It is recently estimated that about 47 million U.S. adults have MS. Worldwide it has been shown that the emerging epidemic of obesity and type 2 diabetes in young kids is due to the shifts in modern diet, which likely influence the disease processes in increasingly younger populations. ³ The most prevalent disease processes inducing weight gain, insulin resistance, hypertension and hyperlipidemia in humans are usually due to high intake of refined carbohydrates, specifically high fructose and diets rich in saturated fat. ^{4–7} One of the underlying risk factors for MS, atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated serum triglyceride

and apolipoprotein B (apoB), increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C). Regardless of cause this syndrome identifies individuals at a high risk for ASCVD.² A growing body of evidence suggests that a pro-inflammatory state and the existence of a profile of inflammatory markers denotes a very high risk for MS and hence cardiovascular diseases.⁸ One of the most predominant underlying risk factors for the syndrome appears to be abdominal obesity, which involves abnormalities in adipose tissue metabolism.⁹ This causes an increased production of pro-inflammatory cytokines, while at the same time there is a decrease in the levels of the potentially protective adipokine, adiponectin, emphasizing the connection between obesity and inflammation.^{2,10} Other major risks include insulin resistance that directly pre-disposes individuals to type 2 diabetes. Furthermore the upper body obesity co-relates strongly with insulin resistance.¹¹ A number of studies document the evidence that an impaired non-esterified fatty acid (NEFA) metabolism contributes to the insulin-resistant state, which is prevalent in individuals with visceral obesity. Hypertrophied intra-abdominal adipocytes are characterized by a hyperlipolytic state that is resistant to the antilipolytic effect of insulin.^{12,13} The resulting NEFA flux to the liver may impair liver metabolism, leading to increased hepatic glucose production. Hepatic insulin resistance is associated with decreased apolipoprotein B degradation and increased production of triacylglycerol-rich lipoproteins.¹⁴ The lymphatic system plays an important role in the uptake and transport of lipids from the intestine to circulation as well as plays a vital role in immune cell trafficking and eliciting an immune response.^{15,16} The lymphatic system with its network of vessels and lymph nodes is closely associated with the specialized adipocytes as well as immune cells all of which interact together in the lymphatic vessels are a critical conduit of interstitial fluid transport and immune cell traffic.¹⁷ Recent reports suggest that the lymphatic role in lipid transport is an active and intricate process, and that when lymphatic function is compromised, there are systemic consequences to lipid metabolism and transport.¹⁸ In spite of the vital roles played by the lymphatic system in both lipid transport and immune surveillance, the pathophysiology of this system has not been studied widely in the context of metabolic syndrome and a wide gap remains in our understanding. This review aims to bring together what we know about the various facets of MS and the roles played by the lymphatic system in modulating lipid transport/metabolism and inflammation, which are central to the onset and progression of this disease.

Introduction to the lymphatic system

The lymphatic system that runs in parallel with the blood vascular system plays an important role in the maintaining body-fluid homeostasis, immune cell trafficking and lipid transport from the intestinal lacteals.^{19, 18} To accomplish its normal functions, the lymphatic system, with its network of lymphatic vessels and interconnected lymph nodes must transport lymph from the interstitial spaces, into and through the lymphatics, through the lymphatic compartment of the nodes, back into the nodal efferent lymphatics and eventually empty them into the great veins.^{20,19} This movement of lymph which contains immune cells, antigens, lipids, macromolecules, fluid and particulate matter within the lymphatic network, from where it is formed in the initial lymphatics to its final exit into the venous compartment is primarily determined by the inherent pressure gradients within that network.^{21,22} What is critically important is that the generation of lymph flow by intrinsic forces and the regulation of flow by both intrinsic and extrinsic forces, rely on the phasic and tonic contraction of lymphatic muscle to produce a controlled net unidirectional transport of lymph.²¹ The intrinsic pump relies on the spontaneous contractions of the muscle cells located within the wall of the lymphangion, a section of lymphatic between two adjacent valves,^{23,24} to generate the pressure gradient required to drive lymph flow centrally. The extrinsic lymph pump depends on the cyclical compression and expansion of the lymphatic by the action of the surrounding tissues (blood vessel pulsations, gastrointestinal muscle

contractions, heart contractions, skeletal muscle contractions, breathing movements, etc.) to generate lymph flow.^{20, 25–28} The initial lymphatics or lymphatic capillaries are blind ended tubes comprised of single-cell layer of overlapping endothelial cells without continuous basement membrane. They are uniquely tethered to the surrounding interstitial matrix through characteristic “anchoring filaments”.^{29–31} The muscle cell layers invested in the outer walls of collecting and transport lymphatic vessels generate and control the movement of lymph along the lymphatic network, even against significant opposing pressure gradients. We have recently shown that lymphatic muscle contains both striated and SM contractile elements.³² Furthermore our data show that there are differences in the contractile machinery between blood vessels and lymphatics as well as among lymphatics from various tissue beds. However the mechanisms of lymphatic contraction under normal condition and how they are modulated during the disease processes are not completely understood.

Lymph flow is the result of a complicated combination of lymph formation, intrinsic and extrinsic forces/pumps.²¹ Lymphatic pump function is very sensitive to changes in mechanical load; it is likely that changes in these loads on the lymphatic system of the gut are an important regulator in lipid transport.¹⁸ Controlled studies of the influences of imposed flow on lymphatic contractile activity were performed in isolated rat lymphatics.^{33,34} Results from these studies showing a flow-dependent inhibition of the active lymph pump support the concept that the pumping activity of the lymphatics is regulated by flow/shear to adapt to the local needs to transport lymph through a continuous modulation of the extrinsic and intrinsic flows. At low levels of lymph inflow in the transporting lymphatics (i.e. low extrinsic flows), the influences of intrinsic pump will dominate with periodic NO release due to the phasic flow/shear patterns of the lymph pump to maintain efficient lymph transport. When the levels of lymph formation and inflow to the transporting lymphatics rise (i.e. high extrinsic flows), the influences of extrinsic forces will dominate, leading to a high NO release that inhibit the intrinsic pumping and basal tone of the transport lymphatics to optimize the conduit function of the vessel.²¹ Interestingly, when lymphatic vessels isolated from various regions in the rat were compared, mesenteric lymphatics were found to be the least sensitive to this flow inhibition.³⁴ This is particularly important in light of the fact that the changes in load experience postprandially by a mesenteric lymphatic are presumably substantial¹⁸. Failures in lymphatic transport can result in lymphedema marked by Increased lipid accumulation throughout the body resulting as an outcome of surgical procedures or acquired pathologically resulting in significant accumulation of fluid, matrix remodeling and adipose expansion in the affected limb.³⁵ However, the exact mechanisms connecting lipid pathologies (e.g. hyperlipidemia, hypercholesterolemia, obesity and diabetes) with lymphatic physiology remain unknown.¹⁸

Lymphatics and lipid transport

The lymphatic system serves as the entry point for nearly all dietary lipids, which are taken up by enterocytes (epithelial cells on the lumen of the intestine) and packaged as large lipoproteins chylomicrons for export into the lymphatic system.^{36, 18, 16} The mesenteric lymphatics are a special access site for ingested macromolecular lipoproteins, including the well-known pro-pathogenic low-density lipoprotein (LDL), which will then be transported through lymphatic system into the blood circulation. In the mesentery, a network of lacteals associated with the intestinal villi act as the initial destination for chylomicrons, cholesterol, apolipoproteins, and other lipid carrier molecules that are released into the interstitium by mucosal enterocytes.³⁷ First, the chylomicrons enter the initial lymphatics of the small intestine, the lacteal and are propelled through the initial vessels by the intestinal peristalsis.³⁸ These lymphatics are typically noted by lack of muscle cells, a discontinuous basement membrane, endothelial cells with gaps between adjacent cells and special connections to the

surrounding matrix called anchoring filaments.^{29–31} This structural feature makes them ideal for the absorption of the large macromolecules of lipoproteins. Movement of this absorbed lipid through the rest of the lymphatic system occurs by the contraction of the muscular collecting lymphatics.¹⁸ Proper functioning of the lymphatic system is essential for modulation of the rate of the chylomicron transport and mixture of chylomicrons with lymph gives the lymphatic system its characteristic ‘milky’ appearance and referred to as chyle. Chylomicrons are the largest (1,000 nm) and the least dense (less than 0.95) of the lipoproteins. They are made up of 85 to 88% triglycerides, and approximately 8% phospholipids, 3% cholesterol esters, 1 to 2% proteins and 1% cholesterol. Chylomicrons contain several types of apolipoproteins including apo-AI, II and IV, apo-B48, apo-CI, II and III, apo-E and apo H.³⁹ Analysis of human lymph showed that the lymph concentration of HDL cholesterol was 30% greater than that of blood.⁴⁰ Experiments on apolipoprotein B knockout mice have shown that apo-B is essential for the formation of chylomicron but is probably not the rate-limiting step. Hayashi et al.⁴¹ demonstrated that an intraduodenal infusion of lipid causes a surge in lymphatic triglyceride output by seven- to eight-fold. However, there is no distinct change in apo-B output in the lymph that is indicative of the chylomicron production by the small intestine.⁴¹ Miura et al.⁴² have demonstrated that lipid absorption from intestinal mucosa lead to an increased flux of lymphocyte transport by almost 10 fold and this increase in lymph flow is enhanced before lipid absorption has reached its maximum. Cholesterol is transported mainly as esterified cholesterol and almost exclusively by the lymphatic system.⁴³ During fat absorption, a significant and gradual increase in lymph flow has been demonstrated, which is referred to as the lymphagoc effect.³⁷ The lymphagoc effect generally spikes at approximately 1–2 hours post feeding and then declines back to basal levels. Many studies have shown that extrinsic pump factors such as increased vascular permeability/capillary filtration, vis a tergo (formation of lymph), and peristaltic motions of the gut contribute to the increase in lymph flow.^{37,44,45} However, relationships between the lipid uptake and mesenteric lymphatic function, and/or the effects of changes in the lipid or protein components of the lymph in modulating lymphatic contractility have not been established. As the mesenteric lymphatic vessels are primary routes of transport for chylomicrons and gut signaling peptides, chronic exposure to the increased transport stress load may result in functional consequences or long term remodeling. Also, increased chylomicron loads likely alter lymph viscosity thereby affecting force production, lymph flow, and shear stresses produced by flow. We have recently demonstrated that low-density lipoprotein (LDL) increases phasic contraction frequency and decreases tone of the isolated rat mesenteric lymphatic vessels, resulting in a significantly increase in lymph pump output.⁴⁶ LDL particles are readily taken up by both the lymphatic muscle and endothelial cell populations. Furthermore our recent results show that mesenteric lymphatics from high-fructose (HF) diet fed rats exhibit an increase in contraction frequency but a decrease in phasic contraction amplitude, a significant decrease in flow-mediated contraction frequency inhibition and a decrease in tone-response to flow (unpublished observation). We have also recently demonstrated that aging affects both phasic and tonic lymphatic contractility by weakening the pressure-dependent contractile/pumping activity of the lymphatic muscle cells and by compromising the endothelium/flow/NO-dependent regulation.⁴⁷ We propose that aged-group animals showing the increasing incidence of insulin resistance, hyperlipidemia and other cardiovascular defects could itself serve as a metabolic syndrome model. The pathophysiology of lymphatics in aged group animals correlate with our recent findings in the mesenteric lymphatic pump activity from the high-fat diet group animals, as we discussed above.

The presence of free chyle in the peritoneum or thoracic cavity, chylous ascites and chylothorax, respectively, is indicative of a dysfunctional lymphatic transport.⁴⁸ Genetic mutations in several genes that are important for lymphatic vascular patterning and development lead to an edematous condition or formation of chylous ascites (reviewed in

Tammela, et al., 2005).⁴⁹ Mice deficient in angiopoietin 2 exhibit lymphatic dysfunction and abnormal patterning of the lymphatic vasculature, develop chylous ascites and edema.⁵⁰ In many individuals with lymphatic syndromes such as lymphedema and lipedema, accumulation of adipose tissue has been found in the edematous regions.⁵¹ Subcutaneous adipose tissue accumulation has been described in the Chy mouse model of lymphedema, in which the cutaneous lymphatic vessels are dysfunctional.⁵² An interesting insight into the fact that lymphatic vascular defects resulting in abnormal leakage or accumulation of lymph might promote adipogenic differentiation, adipocyte lipid accumulation or both, and thereby trigger obesity noted from studies in Prox1+/- mice. At E14.5, all Prox1+/- embryos had edema, indicative of lymphatic dysfunction with the most severe mispatterning being associated with the most pronounced edema.⁵³ The lymphatic vessels of the mesentery and the intestine were the most severely affected in these mice. Pups that died soon after birth showed accumulation of fat in the intestinal wall as well as chyle leakage from the mesenteric lymphatic vessels. In most Prox1+/- mice analyzed, the magnitude of obesity was correlated to the extent of disorganization and leakage of the lymphatic vessels with the oldest and most obese mice having the most severely disrupted lymphatics. Further, the accumulation of fat, most obviously around lymph nodes and near mesenteric lymphatic vessels, suggested that lymphatic leakage was a key mechanism by which lymphatic defects promoted adipocyte hypertrophy or ectopic adipogenesis.⁵³ The authors propose lymphatic vascular defects cause obesity in Prox1+/- mice and that crosstalk occurs between the lymphatic vasculature and adipose tissue.⁵³

Inflammation and metabolic syndrome

Chronic subclinical inflammation is an intrinsic part of metabolic syndrome and several studies have shown that a pro-inflammatory state is an important component of this disease.⁵⁴ A generally enhanced adipose tissue-derived cytokine expression may be another plausible mechanism for the inflammation/MS relationship.⁵⁵ Several chemokines, cytokines, kinases, and transcription factors have been implicated in adipose inflammation, systemic insulin resistance, and a chronic inflammatory atherogenic state that contributes to type 2 diabetes and atherosclerosis.⁵⁶ Adipose tissue is not only specialized in the storage and mobilization of lipids but it is also a remarkable endocrine organ releasing numerous cytokines, and proinflammatory molecules such as interleukin (IL)-6 and tumour necrosis factor- α (TNF- α).¹⁴ The discovery that TNF- α is overexpressed in the adipose tissue of obese mice provided the first clear link between obesity, diabetes and chronic inflammation.⁵⁷ Although inflammatory markers presently do not constitute the diagnostic criteria of MS, the inflammatory markers that have been linked include C-reactive protein (CRP), TNF- α , and interleukin-6 (IL-6).⁵⁸ Macrophage infiltration of adipose tissue has been reported in obese patients that could be cause for the inflammatory profile that has been detected in abdominally obese patients. Lemieux et al.,⁵⁹ have shown that elevated plasma levels of CRP that has a predictive risk for myocardial infarction is increased in viscerally obese patients. Adiponectin is a unique adipokine whose expression from the adipose tissue is inversely correlated with the risk factors underlying MS as insulin resistance, diabetes and atherosclerotic CVD.⁵⁶ It increases fatty acid oxidation while reducing glucose production in liver, suppresses TNF actions in nonalcoholic fatty liver disease and inhibits NF κ B and monocyte adhesion to endothelial cells. The link between inflammatory and metabolic signaling depends on a delicate balance.⁶⁰ Chronic inflammation may represent a triggering factor in the origin of the MS: stimuli such as over nutrition, physical inactivity, and aging may result in cytokine hypersecretion and eventually to insulin resistance and diabetes in genetically or metabolically predisposed individuals. Alternatively, resistance to the anti-inflammatory actions of insulin may result in enhanced circulating levels of proinflammatory cytokines resulting in persistent low-grade inflammation. For example, the neuropeptide Substance P (SP) is an important mediator of inflammation and local release of

SP has been shown to cause chronic inflammatory conditions. In the intestine, SP produced by several cell types may act locally in the mesenteric network in a paracrine fashion.⁶¹ Recently, a role for SP has been shown in appetite regulation and metabolism, in addition to the already established effects of this peptide in gastric motility and digestion.⁶²

Lymphatic system and modulation of immune function and inflammation

Through its function to propel lymph, the lymphatic system is strongly implicated in the adaptive immune response. It transports antigens to lymphoid tissues to allow initiation of an immune response during disease and in response to infections. Lymphoid structures such as lymph nodes are distributed along the lymphatic vessel network. They are composed of lymphatic and blood vessels spread out inside a parenchyma, subdivided into B-cell follicles and a T-cell area that together form the cortex and the medulla. Cellular and molecular traffic between these compartments is an essential aspect of lymph node physiology. An important feature of inflammation is infiltration of inflamed tissues by immune cells such as neutrophils, eosinophils and macrophages.²² Lymphatic vessels are actively involved in the inflammatory responses by transporting leukocytes from the site of inflammation to secondary lymphoid organs. Upon exposure to an inflammatory stimulus and recognition of pathogen-associated molecular patterns, dendritic cells (DC) capture antigens in peripheral tissues and migrate through afferent lymphatic vessels into lymph nodes.⁶³ Several studies have shown that the classical inflammatory mediators, such as prostanoids,^{64–69} histamine,^{70–74} or nitric oxide⁷⁵ modulate the lymphatic pumping and drainage. In addition, the neuromediators that are important in immune and inflammatory responses, such as SP, calcitonin gene related peptide (CGRP), neuropeptide Y or vasoactive intestinal polypeptide, are reported to strongly affect lymphatic vessel contractility.^{76–81} Thus there are substantial evidences that the lymphatic system is intimately involved in and highly altered during inflammatory diseases. Release of inflammatory mediators, in addition to increasing vascular permeability during inflammation is thought to play a pivotal role in modulating lymphatic vessel function.⁵⁸ Recent data from our laboratory suggest that stimulation of SP an important modulator of lymphatic contractility activates inflammatory pathways (Chakraborty et al., unpublished data). SP plays an important role in modulating immune responses and a local release of SP in lymph nodes may contribute to chronic inflammatory conditions.⁸² SP directly stimulates lymphocytes and augments mitogen and antigen induced lymphocyte proliferation.⁸³ SP receptors have been found on around 40% blood lymphocytes and it increases lymphocyte trafficking and proliferative responses in mesenteric lymph nodes and Peyer's patches. It induces immune cells to produce pro-inflammatory cytokines like IL-1, IL-6, TNF α , interferon γ (IFN γ), GM-CSF, and SCF.⁸⁵ Recently, we have recently found a significantly greater amount of adipose tissue deposition around mesenteric lymphatic vessels from rats fed the high fructose diet, which leads to smaller diameter mesenteric lymphatics with a decrease in pumping activity. Furthermore, the SP-induced effect on the lymphatics is completely abolished in rats fed the HF diet, indicating that these mesenteric lymphatics are sensitized to SP (unpublished data). We have previously shown that SP (10nM) increased both contractile frequency and strength of mesenteric lymphatics, and improved the pump efficiency independent of the effects of preload and broadening of the working range of the lymphatic pump.⁷⁷ Karagiannides et al.⁸⁵ have also shown that SP increases mesenteric preadipocyte viability, reduces apoptosis, and stimulates proliferation of fat tissue, creates a pro-inflammatory state and contributes overall to the process of gut inflammation. In addition, SP has been implicated as an anti-obesity target.^{85,86} It has also been shown that both lymph and the lipid-rich chylomicron fraction of lymph promote the differentiation of adipocyte precursors.⁸⁷

Adipose tissue activation and link with lymphatics

Lymphatic vessels mediate lipid absorption and transport, share an intimate spatial association with adipose tissue, and regulate the traffic of immune cells that rely on specialized adipose tissue depots as a reservoir of energy deployed to fight infection.^{17,53} Subcutaneous adipose tissue lies in close proximity to the dermal lymphatic vasculature, while visceral adipose tissue surrounds the collecting lymphatic vessels of the mesentery, cisterna chyli and thoracic duct, as well as the efferent and afferent lymphatic vessels of intra-abdominal lymph nodes. The efferent and afferent lymphatic vessels of the superficial lymph nodes are also encapsulated by adipose tissue.⁵³ Pond and Mattacks (2002)⁸⁸ have shown that sustained local activation of a single popliteal lymph node recruits additional adipocytes in the node-containing depots and these inflammatory signals spread from lymph nodes to surrounding adipocytes. Prolonged inflammation stimulated lipolysis in adipocytes closer to the periphery of the lymph node fat pad, as well as in adipose depots further from the site of application of the inflammatory lipopolysaccharide. Chronic inflammation of the peripheral lymph nodes of rats has been shown to increase the number of adipocytes that surround the node.⁸⁹ In the *Prox*^{+/-} mouse model with the lymphatic vascular disruption causing adult onset obesity, the authors propose two possible mechanisms of inflammation-stimulated adipose tissue accumulation, one where chronic inflammation could promote an increase in adipose tissue mass in order to fulfill the energy requirements of sustained immune cell activation by means of direct immune cell– adipocyte signaling events; and a second mechanism whereby chronic inflammation could promote increased adipogenesis by stimulating neo-lymphangiogenesis in the mesentery of *Prox1*^{+/-} mice, thereby exacerbating the release of lymph-derived adipogenic stimuli.^{53,17}

Conclusions and remaining challenges

Despite a close association of the lymphatic system with adipose tissue and its important function in the transport of dietary lipids as well as in eliciting an inflammatory response, the lymphatic system has been grossly understudied with respect to metabolic disorders. Dysfunction of the lymphatic system can lead to altered lipid transport and fat depositions, and can lead to lymphedema along with progress of the metabolic risk factors underlying metabolic syndrome. A number of recent studies suggest that while these studies have provided important information relating to independent issues, such as obesity, insulin resistance, general inflammation, etc., the important challenge in this area is to identify the central locus that will provide a comprehensive understanding of complex nature of MS. Further studies are required to delineate the axis between lymph transport, lipid metabolism and the development of MS, which will truly be a major paradigm-shift and will provide novel insights in understanding the pathogenesis of MS.

Acknowledgments

This work was supported by AHA 09POST2280005 to SC, RO1HL070308 to DCZ and NIH RO1 HL080526 and KO2 HL086650 to MM.

References

1. GRUNDY SM. Obesity, metabolic syndrome, and cardiovascular disease. *J Clin Endocrinol & Metab.* 2004; 89:2595–2600. [PubMed: 15181029]
2. GRUNDY SM, CLEEMAN JL, DANIELS SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. American Heart Association; National Heart, Lung, and Blood Institute. *Circulation.* 2005; 112:2735–52. [PubMed: 16157765]

3. BASCIANO H, FEDERICO L, ADELI K. Fructose, insulin resistance, and metabolic dyslipidemia. *Nutr Metab (Lond)*. 2005; 2:5. [PubMed: 15723702]
4. FESKENS EJ, VIRTANEN SM, RÄSÄNEN L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. *Diabetes Care*. 1995; 18(8):1104–12. [PubMed: 7587845]
5. HILL JO, LIN D, YAKUBU F, et al. Development of dietary obesity in rats: influence of amount and composition of dietary fat. *Int J Obes Relat Metab Disord*. 1992; 16:321–33. [PubMed: 1319966]
6. ROMIEU I, Willett WC, Stampfer MJ, et al. Energy intake and other determinants of relative weight. *Am J Clin Nutr*. 1988; 47:406–12. [PubMed: 3348153]
7. LIU S, MANSON JE. Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease. *Curr Opin Lipidol*. 2001; 12:395–404. [PubMed: 11507324]
8. PEARSON TA, MENSAH GA, ALEXANDER RW, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003; 107:499–511. [PubMed: 12551878]
9. TRAYHURN P, WOOD IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. *Br J Nutr*. 2004; 92:347–355. [PubMed: 15469638]
10. YOU T, YANG R, LYLES MF, et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. *Am J Physiol Endocrinol Metab*. 2005; 288:E741–E747. [PubMed: 15562250]
11. ROSS R, FREEMAN J, HUDSON R, et al. Abdominal obesity, muscle composition and insulin resistance in premenopausal women. *J Clin Endocrinol Metab*. 2002; 87:5044–5051. [PubMed: 12414870]
12. MITTELMAN SD, VAN CITTERS GW, KIRKMAN EL, et al. Extreme insulin resistance of the central adipose depot *in vivo*. *Diabetes*. 2002; 51:755–761. [PubMed: 11872676]
13. MAURIÈGE P, Marette A, Atgié C, et al. Regional variation in adipose tissue metabolism of severely obese premenopausal women. *J Lipid Res*. 1995; 36:672–684. [PubMed: 7616115]
14. DESPRÉS JP, LEMIEUX I. Abdominal obesity and metabolic syndrome. *Nature*. 2006; 444:881–7. [PubMed: 17167477]
15. MITEVA DO, Rutkowski JM, Dixon JB, et al. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. *Circ Res*. 2010; 106:920–931. [PubMed: 20133901]
16. IQBAL J, HUSSAIN MM. Intestinal lipid absorption. *Am J Physiol Endocrinol Metab*. 2009; 296:E1183–E1194. [PubMed: 19158321]
17. HARVEY NL. The link between lymphatic function and adipose biology. *Ann N Y Acad Sci*. 2008; 1131:82–8. [PubMed: 18519961]
18. DIXON JB. Lymphatic lipid transport: sewer or subway? *Trends Endocrinol Metab*. 2010 Jun 10.
19. MUTHUCHAMY M, ZAWIEJA D. Molecular regulation of lymphatic contractility. *Ann N Y Acad Sci*. 2008; 1131:89–99. [PubMed: 18519962]
20. ZAWIEJA D. Lymphatic biology and the microcirculation: past, present and future. *Microcirculation*. 2005; 12:141–50. [PubMed: 15804980]
21. GASHEV AA, ZAWIEJA DC. Hydrodynamic regulation of lymphatic transport and the impact of aging. *Pathophysiology*. 2010:652.
22. VON DER WEID PY, MUTHUCHAMY M. Regulatory mechanisms in lymphatic vessel contraction under normal and inflammatory conditions. *Pathophysiology*. 2009
23. MISLIN H. Experimental detection of autochthonous automatism of lymph vessels. *Experientia*. 1961; 17:29–30. [PubMed: 13771288]
24. MISLIN, H. Structural and functional relations of the mesenteric lymph vessels, *New Trends in Basic Lymphology*. *Experientia Suppl*; Proceedings of a Symposium; Charleroi (Belgium). July 11–13, 1966; 1966. p. 87-96.

25. ALLEN JM, MCHALE NG. Neuromuscular transmission in bovine mesenteric lymphatics. *Microvasc Res.* 1986; 31:77–83. [PubMed: 3007944]
26. ZAWIEJA DC, DAVIS KL, SCHUSTER R, et al. Distribution, propagation, and coordination of contractile activity in lymphatics. *Am J Physiol.* 1993; 264:H1283–H1291. [PubMed: 8476104]
27. MCHALE NG, MEHARG MK. Co-ordination of pumping in isolated bovine lymphatic vessels. *J Physiol.* 1992; 450:503–512. [PubMed: 1432715]
28. CROWE MJ, VON DER WEID PY, BROCK JA, DF, et al. Coordination of contractile activity in guinea-pig mesenteric lymphatics. *J Physiol.* 1997; 500:235–244. [PubMed: 9097947]
29. LEAK L, BURKE J. Ultrastructural studies on the lymphatic anchoring filaments. *J Cell Biol.* 1968; 36:129–149.
30. COLLIN H. The ultrastructure of conjunctival lymphatic anchoring filaments. *Exp Eye Res.* 1969; 8:102–105. [PubMed: 5786859]
31. LEAK LV. The structure of lymphatic capillaries in lymph formation. *Fed Proc.* 1976; 35:1863–1871. [PubMed: 1269772]
32. MUTHUCHAMY M, GASHEV A, BOSWELL N, DAWSON N, ZAWIEJA D. Molecular and functional analyses of the contractile apparatus in lymphatic muscle. *FASEB J.* 2003; 17:920–922. [PubMed: 12670880]
33. GASHEV AA, DAVIS MJ, ZAWIEJA DC. Inhibition of the active lymph pump by flow in rat mesenteric lymphatics and thoracic duct. *J Physiol.* 2002; 540:1023–1037. [PubMed: 11986387]
34. GASHEV AA, DAVIS MJ, DELP MD, et al. Regional variations of contractile activity in isolated rat lymphatics. *Microcirculation.* 2004; 11:477–492. [PubMed: 15371129]
35. WARREN AG, BRORSON H, BORUD LJ, et al. LYMPHEDEMA: a comprehensive review. *Ann Plast Surg.* 2007; 59:464–472. [PubMed: 17901744]
36. PHAN CT, TSO P. Intestinal lipid absorption and transport. *Front Biosci.* 2001; 6:D299–D319. [PubMed: 11229876]
37. EELC, ZHENG S, YAO L, TSO P, et al. Lymphatic absorption of fatty acids and cholesterol in the neonatal rat. *Am J Physiol Gastrointest Liver Physiol.* 2000; 279:G325–31. [PubMed: 10915641]
38. COLLAN Y, KALIMA TV. The lymphatic pump of the intestinal villus of the rat. *Scand J Gastroenterol.* 1970; 5:187–196. [PubMed: 5429880]
39. FANOUS MY, PHILLIPS AJ, Windsor JA. Mesenteric lymph: the bridge to future management of critical illness *JOP.* 2007 Jul 9; 8(4):374–99.
40. NANJEE MN, et al. Composition and ultra structure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids. *J Lipid Res.* 2001; 42:639–648. [PubMed: 11290836]
41. HAYASHI H, FUJIMOTO K, CARDELLI JA, et al. Fat feeding increases size, but not number of chylomicrons produced by small intestine. *J Physiol.* 1990; 259:G709–G719.
42. MIURA, SEKIZUKA SE, NAGATA H, et al. Increased lymphocyte transport by lipid absorption in rat mesenteric lymphatics. *Am J Physiol.* 1987; 253:G596–600. [PubMed: 3688227]
43. NORDSKOG BK, PHAN CT, NUTTING DF, et al. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. *Adv Drug Deliv Rev.* 2001; 50:21–44. [PubMed: 11489332]
44. TSO P, BALINT JA. Formation and transport of chylomicrons by enterocytes to the lymphatics. *Am J Physiol.* 1986; 250:G715–26. [PubMed: 3521320]
45. TSO P, PITTS V, GRANGER DN. Role of lymph flow in intestinal chylomicron transport. *Am J Physiol.* 1985; 1249:G21–28. [PubMed: 4014464]
46. WANG W, MUTHUCHAMY M, ZAWIEJA DC. Low density lipoprotein modulates rat mesenteric lymphatic pumping. *FASEB J.* 2009; (764.1)
47. GASHEVA OY, KNIPPA K, NEPIUSHCHIKH ZV, et al. Age-related alterations of active pumping mechanisms in rat thoracic duct. *Microcirculation.* 2007; 14:827–839. [PubMed: 17924280]
48. RUTKOWSKI JM, DAVIS KE, SCHERER PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. *FEBS J.* 2009; 276:5738–5746. [PubMed: 19754873]

49. TAMMELA T, PETROVA TV, ALITALO K. Molecular lymphangiogenesis: new players. *Trends Cell Biol.* 2005; 15:434–441. [PubMed: 16005628]
50. GALE NW, HURSTON G, HACKETT SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. *Dev Cell.* 2002; 3:411–423. [PubMed: 12361603]
51. BRORSON H. Liposuction in arm lymphedema treatment. *Sc and J Surg.* 2003; 92:287–95.
52. KARKKAINEN MJ, SAARISTO A, JUSSILA L, et al. A model for gene therapy of human hereditary lymphedema. *Proc Natl Acad Sci.* 2001; 98:12677–12682. [PubMed: 11592985]
53. HARVEY N, SRINIVASAN S, DILLARD M, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. *Nature Genetics.* 2005; 37:1072–1081. [PubMed: 16170315]
54. FESTA A, D'AGOSTINO R JR, HOWARD G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation.* 2000; 102:42–7. [PubMed: 10880413]
55. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? *Nutr. Metab Cardiovasc Dis.* 2004; 14:228–32.
56. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. *JPEN J Parenter Enteral Nutr.* 2008; 32:638–44. [PubMed: 18974244]
57. HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science.* 1993; 259:87–91. [PubMed: 7678183]
58. TAMAKOSHI K, YATSUYA H, KONDO T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. *Int J Obes Relat Metab Disord.* 2003; 27:443–449. [PubMed: 12664077]
59. LEMIEUX I, PASCOT A, PRUD'HOMME D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. *Arterioscler Thromb Vasc Biol.* 2001; 21:961–967. [PubMed: 11397704]
60. HOTAMISLIGIL GS. Inflammation and metabolic disorders. *Nature.* 2006; 444:860–7. [PubMed: 17167474]
61. SEVERINI C, IMPROTA G, FALCONIERI-ERSPAMER G, et al. The tachykinin peptide family. *Pharmacol Rev.* 2002; 54:285–322. [PubMed: 12037144]
62. GROSS K, KARAGIANNIDES I, THOMOU T, et al. Substance P Promotes Expansion of Human Mesenteric Preadipocytes Through Proliferative and Anti-Apoptotic Pathways. *Am J Physiol Gastrointest Liver Physiol.* 2009; 296:G1012–1019. [PubMed: 19282377]
63. MABY-EL HAJJAMI H, PETROVA TV. Developmental and pathological lymphangiogenesis: from models to human disease. *Histochem Cell Biol.* 2008; 130:1063–1078. [PubMed: 18946678]
64. JOHNSTON MG, GORDON JL. Regulation of lymphatic contractility by arachidonate metabolites. *Nature.* 1981; 293:294–7. [PubMed: 7196995]
65. CHAN AK, VERGNOLLE N, HOLLBERG MD, et al. Proteinase-activated receptor 2 activation modulates guinea pig mesenteric lymphatic vessel pacemaker potential and contractile activity. *J Physiol.* 2004; 560(Pt 2):563–76. [PubMed: 15331674]
66. GAO J, ZHAO J, RAYNER SE, et al. Evidence that the ATP-induced increase in vasomotion of guinea-pig mesenteric lymphatics involves an endothelium-dependent release of thromboxane A₂. *Br J Pharmacol.* 1999; 127:1597–602. [PubMed: 10455315]
67. MIZUNO R, KOLLER A, KALEY G. Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. *American Journal of Physiology.* 1998; 274(Pt 2):R790–796. [PubMed: 9530247]
68. VERGNOLLE N, WALLACE JL, BUNNETT NW, et al. Protease-activated receptors in inflammation, neuronal signaling and pain. *Trends Pharmacol Sci.* 2001; 22:146–52. [PubMed: 11239578]
69. ZHAO J, VAN HELDEN DF. ATP-induced endothelium-independent enhancement of lymphatic vasomotion in guinea-pig mesentery involves P_{2X} and P_{2Y} receptors. *Br J Pharmacol.* 2002; 137:477–487. [PubMed: 12359629]

70. LEWIS GP, WINSEY NJ. The action of pharmacologically active substances on the flow and composition of cat hind limb lymph. *Br J Pharmacol.* 1970; 40:446–60. [PubMed: 4395744]
71. HADDY FJ, SCOTT JB, GREGA GJ. Effects of histamine on lymph protein concentration and flow in the dog forelimb. *Am J Physiol* 1972. 1972; 223:1172–7.
72. MCNAMEE JE. Histamine decreases selectivity of sheep lung blood-lymph barrier. *J Appl Physiol.* 1983; 54:914–8. [PubMed: 6853298]
73. AMELANG E, PRASAD CM, RAYMOND RM, et al. Interactions among inflammatory mediators on edema formation in the canine forelimb. *Circ Res.* 1981; 49:298–306. [PubMed: 7249267]
74. SVENSJO E, ADAMSKI SW, SU K, et al. Quantitative physiological and morphological aspects of microvascular permeability changes induced by histamine and inhibited by terbutaline. *Acta Physiol Scand.* 1982; 116:265–73. [PubMed: 6188327]
75. MIZUNO R, KOLLER A, KALEY G. Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. *Am J Physiol.* 1998; 274(3 Pt 2):R790–6. [PubMed: 9530247]
76. AMERINI S, ZICHE M, GREINER ST, et al. Effects of substance P on mesenteric lymphatic contractility in the rat. *Lymphat Res Biol.* 2004; 2:2–10. [PubMed: 15609922]
77. DAVIS MJ, LANE MM, DAVIS AM, et al. Modulation of lymphatic muscle contractility by the neuropeptide substance P. *Am J Physiol Heart Circ Physiol.* 2008; 295:H587–97. [PubMed: 18539752]
78. WANG W, NEPIYUSHCHIKH Z, ZAWIEJA DC, et al. Inhibition of myosin light chain phosphorylation decreases rat mesenteric lymphatic contractile activity. *Am J Physiol Heart Circ Physiol.* 2009; 297:H726–34. [PubMed: 19525378]
79. AKOPIAN VA, BALASHOV NV, KHANIPOV GF. Effect of calcitonin gene related peptide on lymphatic vessels. *Zh Evol Biokhim Fiziol.* 1998; 34:675–82. [PubMed: 10188235]
80. HOSAKA K, RAYNER SE, VON DER WEID PY, et al. Calcitonin gene-related peptide activates different signaling pathways in mesenteric lymphatics of guinea pigs. *Am J Physiol Heart Circ Physiol.* 2006; 290:H813–22. [PubMed: 16172164]
81. OHHASHI T, OLSCHOWKA JA, JACOBOWITZ DM. Vasoactive intestinal peptide inhibitory innervation in bovine mesenteric lymphatics. A histochemical and pharmacological study. *Circ Res.* 1983; 53:535–8. [PubMed: 6138169]
82. ESTEBAN F, MUÑOZ M, GONZÁLEZ-MOLES MA, et al. Role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. *Cancer Metastasis Rev.* 2006; 25:137–45. [PubMed: 16680578]
83. PAYAN DG. Neuropeptides and inflammation: the role of substance P. *Annu Rev Med.* 1989; 40:341–52. [PubMed: 2471450]
84. NOWICKI M, OSTALSKA-NOWICKA D, KONDRACIUK B, et al. The significance of substance P in physiological and malignant haematopoiesis. *J Clin Pathol.* 2007; 60:749–55. [PubMed: 17172475]
85. KARAGIANNIDES I, POTHOUAKIS C. Substance P, obesity, and gut inflammation. *Curr Opin Endocrinol Diabetes Obes.* 2009; 16:47–52. [PubMed: 19104238]
86. NOUGUES J, REYNE Y, DULOR JP. Differentiation of rabbit adipocyte precursors in primary culture. *Int J Obes.* 1988; 12:321–33. [PubMed: 3198310]
87. KARAGIANNIDES, TORRES ID, TSENG YH, et al. Substance P as a novel anti-obesity target. *Gastroenterology.* 2008; 134:747–55. [PubMed: 18325388]
88. POND CM, MATTACKS CA. The activation of the adipose tissue associated with lymph nodes during the early stages of an immune response. *Cytokine.* 2002; 17:131–139. [PubMed: 11895331]
89. MATTACKS CA, SADLER D, POND CM. The cellular structure and lipid/protein composition of adipose tissue surrounding chronically stimulated lymph nodes in rats. *J Anat.* 2003; 202:551–561. [PubMed: 12846476]